 ABL503TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors SEONGNAM, South Korea, July 9, 2021 PRNewswire -- ABL Bio, Inc. KOSDAQ: 298380, a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of pre-clinical data highlighting the safety and anti-tumor efficacy of ABL503TJ-L14B in the Journal for ImmunoTherapy of CancerJITC. Jointly developed with I-Mab NASDAQ: IMAB, ABL503 is a bispecific antibody combining PD-L1 checkpoint pathway with 4-1BB agonistic activity to overcome the current limitation of PD-L1 therapy and 4-1BB related toxicity. 